Alberto Santagostino
Alberto Santagostino is senior vice-president and head of cell and gene technologies at Lonza Pharma and Biotech.
Articles
Using the ‘Cubic Effect’ to Drive Cell and Gene Therapy Commercialization
February 6th 2020Contract partners must help innovators, especially smaller and virtual companies, consider manufacturability as early as possible in development. This requires focusing on technical and operational performance, as well as cost.
Latest Updated Articles
Published: October 11th 2024 | Updated: October 18th 2024
Buy, Sell, Hold: Cell and Gene Therapy - Part 1
Published: September 10th 2024 | Updated: September 18th 2024
CPHI Milan Announces 2024 CPHI Pharma Award Finalists
Published: February 23rd 2024 | Updated: December 20th 2024
Europa Perspectives: Helping to Navigate the Regulatory System
Published: December 13th 2024 | Updated: December 20th 2024
FDA Creates CDER Center for Real-World Evidence Innovation
Published: December 5th 2024 | Updated: December 20th 2024
Leveraging Advancements in Bioanalytical Testing
Published: December 7th 2024 | Updated: December 20th 2024
Exploring Opportunities for LNP Delivery in mRNA
